• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    MiMedx Group, Inc. (MDXG)

    7.85 Down 0.31(3.80%) Feb 5, 4:00PM EST
    ProfileGet Profile for:
    MiMedx Group, Inc.
    1775 West Oak Commons Court, NE
    Marietta, GA 30062
    United States - Map
    Phone: 770-651-9100
    Website: http://www.mimedx.com

    Index Membership:N/A
    Industry:Medical Appliances & Equipment
    Full Time Employees:386

    Business Summary 

    MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix. The company’s AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas. Through its donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. The company processes the human amniotic membrane utilizing its proprietary PURION Process to produce a safe and effective implant. Its CollaFix technology platform is a collagen fiber technology, developed with its patented cross-linking polymers, designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues in order to augment their repair. MiMedx Group supplies approximately 400,000 allografts for application in the wound care, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare through direct sales force, independent sales representatives, and distributors, as well as through private label or OEM relationships. The company was incorporated in 2008 and is headquartered in Marietta, Georgia.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on MiMedx Group, Inc.

    Corporate Governance 
    MiMedx Group, Inc.’s ISS Governance QuickScore as of Feb 1, 2016 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Parker H. Petit , 77
    Chairman and Chief Exec. Officer
    Mr. William Charles Taylor , 48
    Pres, Chief Operating Officer and Director
    Mr. Michael J. Senken , 58
    Chief Financial Officer, Principal Accounting Officer and VP
    Dr. Conan Young ,
    Director of Research
    Dr. Thomas J. Koob Ph.D., 67
    Chief Scientific Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders